

ASX RELEASE

Benitec Biopharma strengthens its executive management team

Sydney, June 18, 2012

Benitec Biopharma Ltd is pleased to announce the appointment of Mr Carl Stubbings as Chief Business Officer, effective July 1, 2012.

Carl brings a wealth of corporate business, sales and marketing experience to Benitec Biopharma, with over thirty years of background in biotechnology and medical diagnostics combined including extensive international experience, particularly in North America, Latin America, Asia Pacific and Europe.

Previously Carl held the position of Vice President, Sales & Marketing for Focus Diagnostics, a subsidiary of New York Stock Exchange listed Quest Diagnostics, a position he has held since 2007.

Carl will relocate to Sydney to take up the role with Benitec Biopharma, where he will work closely with the CEO, Dr Peter French, on licensing, partnering, co-development and investor relations aiming to increase value for the company's shareholders.

Mr. Stubbings said, "I am delighted to have this opportunity to join Benitec Biopharma at a stage where it is poised to realize the enormous potential of its proprietary gene silencing technology across a broad range of therapeutic applications. I intend to apply the skills and experience I have gained internationally to help drive the company to the next level of commercial success, in Australia and globally."

For Further Information

Dr Peter French

Chief Executive Officer

Tel: +61 (0) 412 457 595

pfrench@benitec.com

www.benitec.com

About Benitec Biopharma

Benitec Biopharma Ltd is developing novel treatments for chronic and life-threatening conditions based on targeted gene silencing activity using a transformational technology: DNA-directed RNA interference (ddRNAi) - sometimes called expressed RNAi. The technology's potential to address unmet medical needs and to cure disease results from its demonstrated ability to permanently silence genes which cause the condition. Importantly, this technology's target gene and related gene pathways will rarely have presented as a therapeutic avenue for research for the traditional small molecule agents, currently accounting for the majority of today's pharmaceutical products.

Founded in 1997 and trading publicly since 2001, Benitec Biopharma is listed on the Australian Securities Exchange (ASX) under the symbol "BLT". Benitec Biopharma aims to deliver a range of novel ddRNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry. Besides a focused R&D strategy in infectious diseases, cancer and chronic cancer-associated pain, Benitec Biopharma is pursuing programs with licensees that have advanced to pre-clinical and/or clinical trials.